Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Karl Heinz Pflüger"'
Publikováno v:
Case Reports in Oncology, Vol 7, Iss 1, Pp 239-245 (2014)
Late effects of therapy for Hodgkin's disease include secondary malignancies like leukemia, lymphoma or solid tumors developing after long periods of latency. Ionizing radiation often causes the last group. The highest risks have been described for i
Externí odkaz:
https://doaj.org/article/61c174cd1e9143c4bf7fd6c6b9b27002
Publikováno v:
Case Reports in Oncology
Case Reports in Oncology, Vol 7, Iss 1, Pp 239-245 (2014)
Case Reports in Oncology, Vol 7, Iss 1, Pp 239-245 (2014)
Late effects of therapy for Hodgkin's disease include secondary malignancies like leukemia, lymphoma or solid tumors developing after long periods of latency. Ionizing radiation often causes the last group. The highest risks have been described for i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80a2f3e5dec562b71908eb99814bb426
http://europepmc.org/articles/PMC3999579
http://europepmc.org/articles/PMC3999579
Autor:
Anna Sureda, Christopher P. Fox, Jürgen Finke, Didier Blaise, Norbert Schmitz, Gülsan Türköz Sucak, Jian J. Luan, Xavier Poiré, Hendrik Veelken, Norbert Claude Gorin, Ariane Boumendil, Karl-Heinz Pflüger, Peter Dreger, Arnold Ganser, Herve Finel
Publikováno v:
Leukemia & Lymphoma, 56(12), 3295-3300
Extra-nodal NK/T lymphoma (ENKTL) is rare and more frequently encountered in East Asia. The role of high-dose therapy and autologous stem cell transplantation (HDT-ASCT) for ENKTL is unclear. Twenty-eight evaluable patients who had undergone HDT-ASCT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4b097ac0afb3ed0af6f232204b05380
https://hdl.handle.net/1887/103992
https://hdl.handle.net/1887/103992
Autor:
Wolfgang E. Berdel, Martina Haibach, Karl Heinz Pflüger, Stefan W. Krause, Christoph Röllig, Gerhard Ehninger, Barbara Ritter, Alwin Krämer, Hubert Serve, Marcus Hentrich, Christian Junghanß, Shabnam Shaid, Michael S. Kramer, Christian Brandts, Eberhard Schleyer, Carsten Müller-Tidow
Publikováno v:
Leukemia & Lymphoma. 53:1062-1067
Sorafenib is a multi-kinase inhibitor with activity against several intracellular kinases which may play a role in the pathogenesis of acute myeloid leukemia (AML). In vitro data and results from early clinical trials suggest that sorafenib might be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11996d8666ef3eba5027372b8a357a0f
https://doi.org/10.3109/10428194.2011.637210
https://doi.org/10.3109/10428194.2011.637210
Autor:
Theo de Witte, Carlo Aul, Hans-Eckart Schaefer, Aristoteles Giagounidis, Stefan Suciu, Ulrich Germing, Pierre W. Wijermans, Michael Lübbert, Björn Rüter, Anne Hagemeijer, Helmut R. Salih, Uwe Platzbecker, Heiko Becker, Boris Labar, Karl-Heinz Pflüger, Arnold Ganser, Petra Muus, Valeria Fiaccadori, Frédéric Baron, Dominik Selleslag
Publikováno v:
Annals of Hematology, 94, 2003-13
Annals of Hematology, 94, 12, pp. 2003-13
Annals of Hematology, 94, 12, pp. 2003-13
Item does not contain fulltext In the European Organisation for Research and Treatment of Cancer (EORTC)/GMDSSG phase III trial 06011, we compared decitabine (15 mg/m(2) every 8 h for 3 days) with best supportive care (BSC) in patients >/=60 years wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abf0e2e99d0769e6fa7568e3b05d3644
http://hdl.handle.net/2066/152103
http://hdl.handle.net/2066/152103
Autor:
R. Pfab, J. Birkmann, W. Zeller, H. H. Gossmann, Hubert Köppler, Karl-Heinz Pflüger, C. Gropp, H. Kuhn, E. U. Steinhauer, Klaus Havemann, E. Lötzke, S. Oehl, Harald Stein, I. Eschenbach, Karl Lennert, P. Drings
Publikováno v:
Hematological Oncology. 9:217-223
In a multicentre phase III trial 146 previously untreated patients with high grade non-Hodgkin's lymphomas stage II–IV were randomized to receive either four cycles of CHOEP (cyclophosphamide 750 mg/m2 iv d 1, doxorubicin 50 mg/m2 iv d 1, vincristi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::098f3b3ecf8307717427957aa102bc61
https://doi.org/10.1002/hon.2900090407
https://doi.org/10.1002/hon.2900090407
Autor:
Ralf Hofheinz, Salah Eddin Al Batran, Norbert Niederle, Hans-Joachim Wilke, Cornelie Haag, Thomas Büchele, Carsten Bokemeyer, Joerg T. Hartmann, Karl-Heinz Pflüger, Lothar Kanz, Hans Edgar Reis, Elke Jäger, Karin Oechsle
Publikováno v:
Anti-Cancer Drugs. 15:473-477
Irinotecan has proven anti-tumor activity as induction treatment in combination with 5-fluorouracil (5-FU) or as second-line treatment after 5-FU in patients with metastatic colorectal cancer. The aim of the present phase II study was to evaluate iri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b51e9c27a7806bf93de0212a3630f0b3
https://doi.org/10.1097/01.cad.0000127144.73043.57
https://doi.org/10.1097/01.cad.0000127144.73043.57
Publikováno v:
Journal of Clinical Oncology. 14:1071-1076
PURPOSE In a phase II trial with paclitaxel and simultaneous radiotherapy in non-small-cell lung cancer (NSCLC) patients, an unexpected high incidence of interstitial pneumonias was observed. The type of immunodeficiency associated with this treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cbe9964cd28073988330245064fa24d
https://doi.org/10.1200/jco.1996.14.4.1071
https://doi.org/10.1200/jco.1996.14.4.1071
Publikováno v:
Annals of Oncology. 5:365-368
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70cddcefb0240d64a8e3636d345102c8
https://doi.org/10.1093/oxfordjournals.annonc.a058842
https://doi.org/10.1093/oxfordjournals.annonc.a058842
Autor:
Arnold Ganser, Theo de Witte, Liliana Baila, Stefan Suciu, Petra Muus, Michael Lübbert, Carlo Aul, Corneel Coens, Björn Rüter, Anne Hagemeijer, Karl-Heinz Pflüger, Aristoteles Giagounidis, F. Beeldens, Boris Labar, Dominik Selleslag, Ulrich Germing, Helmut R. Salih, Pierre W. Wijermans, Hans E. Schaefer, Uwe Platzbecker
Publikováno v:
Journal of Clinical Oncology, 29, 15, pp. 1987-96
Journal of Clinical Oncology, 29, 1987-96
Journal of Clinical Oncology, 29, 1987-96
Purpose To compare low-dose decitabine to best supportive care (BSC) in higher-risk patients with myelodysplastic syndrome (MDS) age 60 years or older and ineligible for intensive chemotherapy. Patients and Methods Two-hundred thirty-three patients (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c8150378ff45b6f8bc4cec58a229e72
https://doi.org/10.1200/jco.2010.30.9245
https://doi.org/10.1200/jco.2010.30.9245